Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
about
Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrationsA new azole derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cellsAdjunctive immune therapy for fungal infections.Antibody immunity and invasive fungal infectionsA 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis.Combination treatment of invasive fungal infections.Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.Animal models: an important tool in mycology.The capsule of the fungal pathogen Cryptococcus neoformans.Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responsesCryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Antibody-based therapies for emerging infectious diseases.Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model.
P2860
Q30530667-559E18C5-B5D3-4871-9296-07ED264F2C5DQ33693515-DBE7FF89-3BBC-43C9-A869-137324329E3FQ33857658-0360E328-4609-44E0-8991-925D184604E2Q33975989-60AF66A8-480C-41F9-968E-2319A7858FAEQ33977602-3F61B867-21BA-45AF-8144-61736E4574CAQ34350401-75CC4EF1-8CBE-4165-B729-11262765B424Q35447692-888D5052-E515-4CC0-B26C-A4FC2EB6787EQ35546266-2D41CEA0-61D3-4B1E-8368-B04181DA27A1Q36011378-FD04E2AB-A3D0-44FD-B7D2-AA48A67EF492Q36095320-886CD847-5BE5-43FE-BD73-7D79EA6E3B37Q37008692-64C199A6-7715-4953-85D7-3215A195742EQ37337879-8045B994-D5B8-466D-A530-82A20EFBFB41Q37562226-3A75EAE3-DCFD-4E69-8471-3C6A309D3AD1Q38154164-0C85CE58-6FC2-4E30-A6CF-2B9DA20D0197Q39228846-2F068055-E3A7-4006-AEC2-DA453BAAF90AQ44208502-ABA403DB-D291-4578-B194-69BA11A3098F
P2860
Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@ast
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@en
type
label
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@ast
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@en
prefLabel
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@ast
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@en
P2093
P2860
P356
P1476
Monoclonal antibodies to Crypt ...... enhance fluconazole efficacy.
@en
P2093
A Casadevall
J Mukherjee
M D Scharff
M Feldmesser
P2860
P304
P356
10.1128/AAC.39.7.1398
P407
P577
1995-07-01T00:00:00Z